Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Assets: 2015-2024

Historic Assets for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $139.8 million.

  • Seres Therapeutics' Assets fell 19.73% to $143.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.5 million, marking a year-over-year decrease of 19.73%. This contributed to the annual value of $139.8 million for FY2024, which is 61.01% down from last year.
  • Per Seres Therapeutics' latest filing, its Assets stood at $139.8 million for FY2024, which was down 61.01% from $358.6 million recorded in FY2023.
  • Seres Therapeutics' 5-year Assets high stood at $358.6 million for FY2023, and its period low was $139.8 million during FY2024.
  • Moreover, its 3-year median value for Assets was $348.8 million (2022), whereas its average is $282.4 million.
  • As far as peak fluctuations go, Seres Therapeutics' Assets skyrocketed by 158.94% in 2020, and later crashed by 61.01% in 2024.
  • Yearly analysis of 5 years shows Seres Therapeutics' Assets stood at $342.9 million in 2020, then rose by 3.48% to $354.9 million in 2021, then fell by 1.71% to $348.8 million in 2022, then grew by 2.81% to $358.6 million in 2023, then plummeted by 61.01% to $139.8 million in 2024.